In baboons, the intravenous administration of piribedil. a dopaminergic agonist, was associated with marked dose dependent increases in CBF and cerebral oxygen consumption. We have studied the effects of piribedil on CBF in 20 normal, human volunteers of comparable ages. Ten received 0.1 mg/kg piribedil intravenously for 30 min; the other ten received 0.2 mg/kg. In the first group, CBF did not vary significantly, in the second group, there was a mean increase in CBF of 21.8% (p � 0.005). In man, as in animals, piribedil provokes an increase of CBF. Key Words: Dopamine agonist Piribedil. (1980) have shown in animals that the manipulation of the dopaminergic systems could alter brain haemodynamics. In anesthetised baboons that recieved a dopaminergic agonist, piribedil, at a dose of 0.1 mglkg and 1 mglkg intravenously, significant increases of CBF (40% and 49%) were observed. In the present study, we demonstrate a similar action of piribedil on CBF in man.
McCulloch and Edvinsson (1980) have shown in animals that the manipulation of the dopaminergic systems could alter brain haemodynamics. In anesthetised baboons that recieved a dopaminergic agonist, piribedil, at a dose of 0.1 mglkg and 1 mglkg intravenously, significant increases of CBF (40% and 49%) were observed. In the present study, we demonstrate a similar action of piribedil on CBF in man.
MATERIALS AND METHODS
Twenty young subjects of similar ages, all volun teers and free of any organic or functional pathol ogy, were studied. Piribedil was given intrave nously by means of a 30-min perfusion, 0.1 mglkg, to ten subjects (Group A), and 0.2 mglkg to the other ten (Group B). In this last group, five subjects received, 20 min before the perfusion, 30 mg of domperidone (a peripheral dopaminergic antagonist that does not cross the blood-brain barrier (Agid et aI., 1979» to diminish the digestive side effects caused by piribedii.
Mean arterial blood pressure (MABP) and ECG were monitored during the perfusion. MABP was obtained by external determination and from the following formula proposed by Burton (1975) :
Cerebral blood flow (FI) was measured by the 133-xenon inhalation method using a 32-detector system (Obrist et aI., 1975; Risberg et aI., 1975) be fore piribedil administration and 10 min after. Fl represents CBF in mlllOO glmin of the fast-flow compartment and it was derived from the initial slope of the isotope clearance curve.
The P aC02 was calculated from the CO2 content in the expired air.
RESULTS
At the dose of 0.1 mglkg, piribedil effected no significant change in the CBF(Fl): 79.8 ml ± 12.9 mIJIOO g/min and 78.8 ± 11 mIJIOO g/min, respec tively, before and after the perfusion (Table O. There was no change in either MABP or Pco2 be fore and after the perfusion. At the dose of 0.2 mg/kg, piribedil effected a mean increase in CBF(FI) of 21.8% (p ,,-:; 0.005); in seven out of ten cases there was a significant increase (�I4%) ( Table 1 ); in two cases we recorded only a slight tendency to increase; finally, in one case there was no change (Fig, 1) . There was no change in MABP (93 ± 12 mm Hg before and 94 ± 10.1 mm Hg after piribedil administration). Digestive side ef fects were marked in five subjects; the dose of 30 mg domperidone 20 min before the perfusion began prevented these side effects in the other five sub jects.
DISCUSSION
The in vitro experiments concerning the action of dopamine and the other dopaminergic agents suggest the presence of specific dopaminergic re ceptors on the smooth muscles of the cerebral vas cular system that cause a vasodilatation (Edvinsson et aI., 1978) . McCulloch and Edvinsson (1980) have shown an action in vivo of piribedil in the anesthetised baboon. They recorded significant in creases of CBF and a dose-dependent increase in the cerebral consumption of oxygen. These effects do not occur if the dopaminergic antagonist, pimozide, is given first. These authors have also demonstrated, in vitro, the weak vasomotor effect of piribedil on the feline middle cerebral artery. On the basis of these observations, McCulloch and Ed vinsson (1980) concluded that piribedil causes, in vivo. a significant increase of CBF and that the vas odilatation is due to an increase of the metabolic demand rather than to a direct vasomotor effect. Kelly and McCulloch (1981) have shown that following administration of the dopamine receptor agonist, apomorphine, it is the metabolic rate of the surrounding tissue that is the primary determinant of local CBF. The administration of piribedil in small doses (0.1 mg/kg) to normal subjects does not cause a signifi cant change in CBF. On the other hand, at a dose of 0.2 mg/kg, we observe a significant increase of CBF, 21.8%, p � 0.005. This increase is global and symmetrical; no preferential pattern can be found. The preliminary administration of a peripheral dopaminergic antagonist (domperidone) does not prevent this CBF increase, but does, however, pre vent the secondary digestive side effects of piribedil.
In conclusion, the results we obtained in normal subjects are in accord with those found in animals and therefore confirm the CBF increase by piribedil; this CBF increase depends upon the dose adminis tered.
